Home › Pituitary ACTH Hypersecretion › NCT03364803
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RecruitingObservational study
Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study
Who can join
Ages 14 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 14 or older * Active or treated overt Cushing's (due to pituitary, ectopic, or adrenal tumor), mild adrenal Cushing's syndrome (MACS), or a silent corticotroph tumor * The diagnosis of CS or MACS will be made by the PI, based on the below Endocrine Society guidelines, the patient's clinical presentation, and the PI's judgment. * Diagnostic criteria for ACTH-dependent Cushing's are according to the Endocrine Society and European Society of Endocrinology guidelines and include: Elevated 24-hour urinary free cortisol (UFC), normal or elevated plasma ACTH, elevated midnight salivary cortisol levels, or classic dexamethasone suppression testing for CD (morning cortisol \> 5 ug/dL after 1 mg overnight of classic 2-day low dose test) and a pituitary lesion on MRI (in the case of pituitary Cushing's). If patient does not have any of these results, pathology of ACTH tumor may confirm presence of disease. * Diagnostic criterion for MACS is according to the European Society of Endocrinology guidelines: Classic dexamethasone suppression testing for CS (morning cortisol \>1.8 µg/dL after 1 mg overnight) and the presence of an adrenal adenoma. * Silent corticotroph tumors will be defined by surgical pathology demonstrating positivity for ACTH, in the absence of clinical and biochemical features of Cushing's syndrome. * In lieu of MRI, surgical, or laboratory reports, physician's assessment note including mention of results will also be used as source for eligibility purposes. Exclusion Criteria: * Patients with a diagnosis of iatrogenic Cushing's.
About the study
The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.
What is being tested
- Cushing's QoL (Quality of Life Questionnaire) (other)
- Nottingham Health Profile (NHP) (other)
- Hospital Anxiety and Depression Scale (HADS) (other)
- Perceived Stress Scale (PSS) (other)
- Barratt's Impulsivity Scale (BIS) (other)
- Beck Depression Inventory (BDI) (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 300 · Started: Nov 28, 2017
Contact the study team
- Eliza Geer, MD · Phone: 646-888-2627
- Marc Cohen, MD · Phone: 212-639-3769
Official record on ClinicalTrials.gov — NCT03364803
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.